(EMN) Eastman Chemical - NYSE
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 8.289m USD | Total Return: -2.3% in 12m
Avg Turnover: 77.2M
EPS Trend: -23.8%
Qual. Beats: 0
Rev. Trend: -73.3%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
Confidence
Eastman Chemical Company (NYSE: EMN) is a U.S.-headquartered specialty materials company founded in 1920 and based in Kingsport, Tennessee. It has been publicly traded since its IPO in October 1993 and is classified within the Materials sector as a diversified chemicals producer, with a mid-cap market capitalization of approximately $8.3 billion.
The company operates through four reporting segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers. These segments collectively serve a broad set of end-markets, including transportation, personal care, wellness, food and feed, agriculture, building and construction, water treatment, energy, electronics, and medical/pharma applications. Its product portfolio spans specialty additives and solvents, copolyesters, cellulosic biopolymers, polyester films, olefin and acetyl derivatives, plasticizers, and cellulose acetate fibers used in filtration media (notably cigarette filters), textiles, and nonwoven materials.
As a diversified chemicals business, Eastmans revenue is tied to a mix of industrial cyclical demand (construction, automotive, durables) and more defensive consumer end-uses (personal care, consumables, filtration). Its Chemical Intermediates segment includes more commodity-oriented products such as olefins and solvents, which typically carry lower margins, while the specialty segments (Advanced Materials, Additives & Functional Products, and Fibers) are generally positioned for higher value-added, performance-driven applications.
- Cellulose acetate tow demand weakens on declining global cigarette consumption
- Advanced Materials margins lift on copolyester pricing and biopolymer demand growth
- Chemical Intermediates margins compress from ethylene feedstock volatility
| Net Income: 399.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 14.91% < 20% (prev 17.43%; Δ -2.52% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.00b > Net Income 399.0m |
| Net Debt (4.66b) to EBITDA (1.18b): 3.94 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.9m) vs 12m ago -2.54% < -2% |
| Gross Margin: 19.77% > 18% (prev 24.83%; Δ -5.06% > 0.5%) |
| Asset Turnover: 57.23% > 50% (prev 62.53%; Δ -5.31% > 0%) |
| Interest Coverage Ratio: 3.12 > 6 (EBIT TTM 664.0m / Interest Expense TTM 213.0m) |
| A: 0.08 (Total Current Assets 4.06b - Total Current Liabilities 2.77b) / Total Assets 15.2b |
| B: 0.66 (Retained Earnings 10.1b / Total Assets 15.2b) |
| C: 0.04 (EBIT TTM 664.0m / Avg Total Assets 15.1b) |
| D: 0.66 (Book Value of Equity 6.01b / Total Liabilities 9.14b) |
| Altman-Z'' = 3.71 = AA |
| DSRI: 1.05 (Receivables 1.22b/1.26b, Revenue 8.64b/9.36b) |
| GMI: 1.26 (GM 24.83% / 19.77%) |
| AQI: 0.99 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 0.92 (Revenue 8.64b / 9.36b) |
| TATA: -0.04 (NI 399.0m - CFO 1.00b) / TA 15.2b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of June 26, 2026, the stock is trading at USD 70.61 with a total of 977,856 shares traded. Over the past week, the price has changed by -2.09%, over one month by -4.01%, over three months by +0.01% and over the past year by -2.30%.
Current recommended Stop Loss: 67.90 (which is 3.8% or 1.2 ATR below the current price).
Eastman Chemical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy EMN.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 84.3 | 19.4% |
P/E Trailing = 20.9509
P/E Forward = 11.2486
P/S = 0.9595
P/B = 1.3795
P/EG = 0.618
Revenue TTM = 8.64b USD
EBIT TTM = 664.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 4.45b USD (from longTermDebt, last quarter)
Short Term Debt = 770.0m USD (from shortTermDebt, last quarter)
Debt = 5.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.66b USD (calculated: Debt 5.33b - CCE 665.0m)
Enterprise Value = 12.9b USD (8.29b + Debt 5.33b - CCE 665.0m)
Interest Coverage Ratio = 3.12 (Ebit TTM 664.0m / Interest Expense TTM 213.0m)
EV/FCF = 26.00x (Enterprise Value 12.9b / FCF TTM 498.0m)
FCF Yield = 3.85% (FCF TTM 498.0m / Enterprise Value 12.9b)
FCF Margin = 5.76% (FCF TTM 498.0m / Revenue TTM 8.64b)
Net Margin = 4.62% (Net Income TTM 399.0m / Revenue TTM 8.64b)
Gross Margin = 19.77% ((Revenue TTM 8.64b - Cost of Revenue TTM 6.93b) / Revenue TTM)
Gross Margin QoQ = 19.80% (prev 17.13%)
Tobins Q-Ratio = 0.85 (Enterprise Value 12.9b / Total Assets 15.2b)
Interest Expense / Debt = 4.0% (Interest Expense 213.0m / Debt 5.33b)
Taxrate = 11.53% (52.0m / 451.0m)
NOPAT = 587.4m (EBIT 664.0m * (1 - 11.53%))
Current Ratio = 1.47 (Total Current Assets 4.06b / Total Current Liabilities 2.77b)
Debt / Equity = 0.89 (Debt 5.33b / totalStockholderEquity, last quarter 6.01b)
Debt / EBITDA = 3.94 (Net Debt 4.66b / EBITDA 1.18b)
Debt / FCF = 9.36 (Net Debt 4.66b / FCF TTM 498.0m)
Total Stockholder Equity = 5.89b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.64% (Net Income 399.0m / Total Assets 15.2b)
RoE = 6.77% (Net Income TTM 399.0m / Total Stockholder Equity 5.89b)
RoCE = 6.42% (EBIT 664.0m / Capital Employed (Equity 5.89b + L.T.Debt 4.45b))
RoIC = 4.59% (NOPAT 587.4m / Invested Capital 12.8b)
WACC = 7.06% (E(8.29b)/V(13.6b) * Re(9.33%) + D(5.33b)/V(13.6b) * Rd(4.0%) * (1-Tc(0.12)))
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -84.11 | Cagr: -1.44%
[DCF] Terminal Value 73.39% ; FCFF base≈528.8m ; Y1≈471.0m ; Y5≈392.6m
[DCF] Fair Price = 14.15 (EV 6.28b - Net Debt 4.66b = Equity 1.62b / Shares 114.3m; r=8.35% [WACC [floored]]; 5y FCF grow -13.39% → 2.50% )
EPS Correlation: -23.76 | EPS CAGR: -4.23% | SUE: 0.22 | # QB: 0
Revenue Correlation: -73.33 | Revenue CAGR: -2.65% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.81 | Chg30d=+0.36% | Revisions=+25% | Analysts=13
EPS next Quarter (2026-09-30): EPS=1.97 | Chg30d=+0.15% | Revisions=+62% | Analysts=13
EPS current Year (2026-12-31): EPS=6.38 | Chg30d=+0.17% | Revisions=+78% | GrowthEPS=+17.7% | GrowthRev=+4.8%
EPS next Year (2027-12-31): EPS=7.01 | Chg30d=-0.05% | Revisions=+47% | GrowthEPS=+9.8% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: +78%